Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits

Every big pharma company relies on a roster of just a few blockbuster drugs -- medicines that reliably bring in more than $1 billion in revenue every year -- to fund its core efforts, and to deliver solid returns to investors. So when a business like Vertex Pharmaceuticals (NASDAQ: VRTX) releases some new data on a potential blockbuster that could be just a few months away from being approved for sale, it's a big development.On that note, let's dive in and investigate how the bull thesis for buying Vertex stock just got even stronger.Vertex's push to diversify its portfolio of medicines away from its traditional wheelhouse, drugs for cystic fibrosis (CF), looks like it's on the verge of bearing fruit once again. On Oct. 20, the company presented new information about its non-opioid oral analgesic candidate, suzetrigine, at the annual meeting of the American Society of Anesthesiologists (ASA).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool